

Preservation of Functionality, Immunophenotype and Recovery of HIV RNA from PBMC's Cryopreserved for >20 years

**John Zaunders, Wayne B Dyer, Kazuo Suzuki,
Angelique Levert, Mitchell Starr and Andrew Lloyd,**

**St Vincent's Hospital, Sydney
Sydney Blood Bank (LifeBlood),
Immunovirology Research Network (IVRN).**

Speaker disclosures

- Kazuo Suzuki is a named inventor on a patent for the Double R assay for intracellular HIV RNA transcripts
- John Zaunders is a named inventor on a patent for the OX40 assay for antigen-specific CD4 and CD8 T cells

PBMC Biobanking at Centre for Applied Medical Research, SVH, Sydney

- **Major commitment for NSW State Reference Lab for HIV, at AMR**
 - **Senior Scientist and 4 full-time staff for trials and biobanking**
 - **Twenty -80°C Freezers**
 - **Four Vapour Phase Liquid Nitrogen tanks**
- **Sydney Blood Bank HIV Research PBMC's**


Sydney Blood Bank Cohort (SBBC) – attenuated *nef*-deleted HIV-1

- 1992 - 5 asymptomatic HIV+ transfusion recipients
- single HIV+ donor, D36, who was also a long-term non-progressor
- normal CD4 T cell counts, after 8-10 years of infection
- Sequenced virus from the SBBC had *nef* / 3'-LTR deleted HIV-1



- 1995/6 - Studied SBBC CD4 and CD8 T cells using fresh blood samples:
- Four colour flow: CD45RA/RO, CD28- and activated CD38+/HLA-DR+
- Compared with age-matched and transfusion-matched HIV neg controls
- Also, compared with other viraemic, untreated HIV+ subjects

Coulter XL flow
cytometer

Representative histograms
from ~1995



Original Fresh Blood CD8 T cell subsets from 1995/6



- CONTROL HIV NEGATIVE COHORT
- SBBC (undetectable plasma HIV RNA)
- SBBC (detectable plasma HIV RNA)

- ▨ TA-LTNP COHORT
- ▩ SA-LTNP COHORT

PBMC cryopreserved in liquid N₂ from 3 Cohorts

- **1995 Old Controls HIV-uninfected from Blood Bank Study n = 20**
- **(mean age 60)**

- **1995 Old HIV+ Untreated, viraemic transfusion-acquired and sexually-acquired HIV-infected subjects n = 12 (mean age 47)**


- **2020 Recent PBMC Anonymous healthy staff donors from 2020 n = 20**
- **(mean age 43) IVRN QAP for PBMC storage**

- **Thawed, treated with DNase 1 (0.1mg/ml) 15 min RT, ~90% viability**


- **Stained with two 18-colour panels (PBMC subsets and T cell subsets)**
- **analysis on a 5-laser Fortessa**
- **T cell subsets in fresh blood samples from staff controls n = 16**
- **(mean age 46)**

PBMC subsets – Monocyte subsets


Gated on CD45+
live cells



Gated on CD45+ live
CD14+ monocytes




CD14 dim CD16+ % M ϕ
<0.0001






PBMC subsets – NK cell subsets

**Gated on CD45+ Live
CD14 neg Lymphocytes**








**Gated on CD45+ live
CD14 neg CD3 neg
CD19 neg Lymphocytes**








18-colour PBMC subsets – B cells, Basophils, mDC and pDC

Gated on CD45+ Live
CD14 neg Lymphocytes




CD4 T cell subsets





CD8 T cell subsets



Gated on CD3+ Live
CD8+ Lymphocytes



CD8 T cell subsets – MAIT cells and activated CD8 T cells



Original Fresh Blood CD8 T cell subsets from 1995/6




- CONTROL HIV NEGATIVE COHORT
- SBBC (undetectable plasma HIV RNA)
- SBBC (detectable plasma HIV RNA)



- ▨ TA-LTNP COHORT
- ▩ SA-LTNP COHORT

CD4 and CD8 T cell subsets – Thawed OLD HIV+ cells vs original fresh blood

CD45RO+ CD4 T cells



CD45RO+ CD8 T cells




**OLD HIV+
CD8 T cells**

**CD25+ CD134+ (OX40) Activation Induced Marker (AIM) assay
of mitogen- and antigen-specific CD4 T cells**


**Gated on CD3+ CD4+
Lymphocytes**

**No stimulation
background
(negative control)**



Polyclonal and antigen specific CD4 T cell responses OX40 AIM (activation induced marker) 48 hour assay


Anti-CD3/CD28/CD2 OX40 AIM+ CD4



**Day 7 proliferation assay
of mitogen- and antigen-specific CD4 T cells**

**Gated on CD3+ CD4+
Lymphocytes**


**No stimulation
background
(negative control)**




Optimal polyclonal T cell stimulation of PBMC *via* TCR *in vitro*

Day 4


Gated on CD4
Unstimulated



Gated on CD4
+ 3/28/2



Cell divisions
+ 3/28/2




Polyclonal TCR cell stimulation of isolated CD4 T cells


Patient's
ACD
Blood

+ RosetteSep
CD4
Enrichment
Cocktail


Ficoll




Cultured for 3
days + IL2




Cultured for 3 days
+ IL2
+ Anti-
CD3/CD28/CD2



Polyclonal and antigen specific CD4 T cell responses 7 day proliferation assay



Cytokine production in 48hr supernatants from Old HIV Uninfected Controls' PBMC cultured with Flu or with anti-CD3/CD28/CD2




Cytometric
Bead Array

Legend Plex


(BioLegend)

Polyclonal and antigen specific CD4 T cell responses 7 day proliferation assay




**Extract RNA to measure
cell-associated HIV RNA**

Double-R assay of HIV-1 DNA and HIV-1 RNA transcripts



IntelliPlex assay




Suzuki et al *J.AIDS HIV Treatment* 2019

πCode assay >27x more sensitive than Real-Time PCR analysis

Old HIV+ donor PBMC optimally stimulated in vitro with anti-CD3/CD28/CD2


RNA extracted after 7 days

Transcripts vs donor's original plasma viral load




Recovery of HIV RNA after > 20 yr storage

Nested PCR of extracted RNA from cultured CD4 at day 7



Recovery of HIV RNA after > 20 yr storage: 4kbp product and sequencing



Oxford Nanopore sequencing of 4kbp product

Sample ID	CA	PR	RT	IN	Drug resistance interpretation
N64 (ID.1758)	none	none	M184V	none	emtricitabine (FTC), lamivudine (3TC)
N65 (ID.1759)	none	none	D67E,T69ins,T215Y	none	zidovudine (AZT), lamivudine (3TC)
N66 (ID.1761)	none	none	none	none	none
N67 (ID.1764)	none	none	none	none	none
N68 (ID.1768)	none	none	none	none	none


CA: Capsid, PR: Protease, RT: Reverse transcriptase, IN: Integrasae

Conclusions

- **PBMC's stored for over 20 years still contained all well defined immune subsets of cells:**
 - **Naïve and memory B cells and plasmablasts**
 - **Basophils, DC subsets, NK cell and monocyte subsets**
 - **CD4 and CD8 naïve and memory subsets**
- **Unique opportunity to compare to original flow analysis when fresh:**
 - **Naïve and memory and CD28- cells correlated very well**
 - **Activated CD4 & CD8 cells in HIV+ patient samples did not survive well**
- **Stored PBMC'S showed polyclonal and recall antigen-specific functions:**
 - **OX40 AIM assays**
 - **Proliferation assays**
 - **Cytokine assays**
- **After 7 days of optimal stimulation for HIV + patient PBMC samples:**
 - **Production of HIV RNA transcripts from latent infection**
 - **Enough RNA was produced for long PCR products for sequencing.**

Future Studies

- **PBMC's stored for over 20 years are important:**
 - **Since late 1990's, most HIV+ patients have been on ART**
 - **Slow progressors, long-term non-progressors or Elite Controllers**
 - **Especially Elite Controllers**
 - **have undetectable plasma viremia without ART**
 - **Regarded as benchmark for functional cure**
- **Elite Controllers have undetectable cell-associated HIV RNA in PBMC *ex vivo***
 - **Need multiple cultures of stimulated CD4 T cells to detect any CA-HIV-RNA**



Acknowledgements



AMR













Angelique Levert
Shannen Butterly
Emma You
Kate Merlin
Bertha Fsadni

Support

Immunovirology Research Network (IVRN)
Denka Inc., Tokyo, Japan

PBMC subsets – B cells, Basophils, mDC and pDC





PBMC subsets – CD8 T cell subsets

